Niacinamide (vitamin B3) supports NAD+ production, which is involved in cellular energy metabolism and DNA repair
Oswaldo Cruz 116, e200634
/ 2.5
The Evidence Here is exactly what the SELECT trial found: 17,604 participants enrolled, all with established cardiovascular disease, BMI of 27 or greater, and no diabetes Primary MACE event rate: 6.5 percent in the semaglutide group versus 8.0 percent in the placebo group Hazard ratio of 0.80 means a 20 percent relative reduction in the risk of heart attack, stroke, or cardiovascular death 95 percent confidence interval: 0.72 to 0.90, meaning the true effect falls within that range with high certainty P value less than 0.001, which is statistically decisive Mean follow-up: 39.8 months Mean weight loss with semaglutide: 9.4 percent of body weight Serious adverse events leading to discontinuation: 16.6 percent in the semaglutide group versus 8.2 percent in the placebo group That last number is a bit concerning
54,56,58,59 Studies with longer follow-up could potentially explore whether this risk factor modification may translate into improved graft survival
adults (46.9%) will meet the criteria for obesity, with no demographic group spared
